NYSE
154.57USD
+1.08 (+0.71%)
We have scored 14 news catalysts on Glaukos Corporation (GKOS) over the past 12 months. The biggest single-day move next to one of them came Apr 30, 2026, when GKOS closed +22.8%: “Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook”. Coverage across the window leans positive (average ticker sentiment +0.45). Most of the impact sits in sector healthcare and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.1B
P/E
—
EPS
—
Beta
0.77
52W range
73.16-191.62
Day range
152.75–156.65
Open
153.70
Prev close
153.49
Volume
500K
Avg volume
934.9K
Dividend
0.00
IPO
2015-06-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Glaukos Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GKOS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
